90 related articles for article (PubMed ID: 23708448)
1. CDK1 links to RARγ in treatment response of cancer cells.
Ødum N
Cell Cycle; 2013 Jun; 12(11):1659-60. PubMed ID: 23708448
[No Abstract] [Full Text] [Related]
2. CDK1 interacts with RARγ and plays an important role in treatment response of acute myeloid leukemia.
Hedblom A; Laursen KB; Miftakhova R; Sarwar M; Anagnostaki L; Bredberg A; Mongan NP; Gudas LJ; Persson JL
Cell Cycle; 2013 Apr; 12(8):1251-66. PubMed ID: 23518499
[TBL] [Abstract][Full Text] [Related]
3. A proteolytic fragment of Mcl-1 exhibits nuclear localization and regulates cell growth by interaction with Cdk1.
Jamil S; Sobouti R; Hojabrpour P; Raj M; Kast J; Duronio V
Biochem J; 2005 May; 387(Pt 3):659-67. PubMed ID: 15554878
[TBL] [Abstract][Full Text] [Related]
4. Differentiation of trophoblast stem cells into giant cells is triggered by p57/Kip2 inhibition of CDK1 activity.
Ullah Z; Kohn MJ; Yagi R; Vassilev LT; DePamphilis ML
Genes Dev; 2008 Nov; 22(21):3024-36. PubMed ID: 18981479
[TBL] [Abstract][Full Text] [Related]
5. Overexpression of retinoic acid receptors alpha and gamma into neoplastic epidermal cells causes retinoic acid-induced growth arrest and apoptosis.
Hatoum A; El-Sabban ME; Khoury J; Yuspa SH; Darwiche N
Carcinogenesis; 2001 Dec; 22(12):1955-63. PubMed ID: 11751425
[TBL] [Abstract][Full Text] [Related]
6. Phospho-p70S6K/p85S6K and cdc2/cdk1 are novel targets for diffuse large B-cell lymphoma combination therapy.
Zhao MY; Auerbach A; D'Costa AM; Rapoport AP; Burger AM; Sausville EA; Stass SA; Jiang F; Sands AM; Aguilera N; Zhao XF
Clin Cancer Res; 2009 Mar; 15(5):1708-20. PubMed ID: 19223503
[TBL] [Abstract][Full Text] [Related]
7. Bortezomib sensitizes human acute myeloid leukemia cells to all-trans-retinoic acid-induced differentiation by modifying the RARα/STAT1 axis.
Ying M; Zhou X; Zhong L; Lin N; Jing H; Luo P; Yang X; Song H; Yang B; He Q
Mol Cancer Ther; 2013 Feb; 12(2):195-206. PubMed ID: 23243061
[TBL] [Abstract][Full Text] [Related]
8. Mimicking the Acute Myeloid Leukemia Niche for Molecular Study and Drug Screening.
Houshmand M; Soleimani M; Atashi A; Saglio G; Abdollahi M; Nikougoftar Zarif M
Tissue Eng Part C Methods; 2017 Feb; 23(2):72-85. PubMed ID: 28007011
[TBL] [Abstract][Full Text] [Related]
9. New alternative phosphorylation sites on the cyclin dependent kinase 1/cyclin a complex in p53-deficient human cells treated with etoposide: possible association with etoposide-induced apoptosis.
Higginbottom K; Jahnke U; Newland AC; Cotter FE; Allen PD
Apoptosis; 2007 Oct; 12(10):1847-55. PubMed ID: 17636382
[TBL] [Abstract][Full Text] [Related]
10. Mechanisms of cell cycle blocks at the G2/M transition and their role in differentiation and development.
Mowat MR; Stewart N
Prog Mol Subcell Biol; 1998; 20():73-100. PubMed ID: 9928527
[No Abstract] [Full Text] [Related]
11. TLS-ERG leukemia fusion protein deregulates cyclin-dependent kinase 1 and blocks terminal differentiation of myeloid progenitor cells.
Pan J; Zou J; Wu DY; Roberson RS; Hennings LJ; Ma X; Yared M; Blackburn ML; Chansky HA; Yang L
Mol Cancer Res; 2008 May; 6(5):862-72. PubMed ID: 18505930
[TBL] [Abstract][Full Text] [Related]
12. CDK1: beyond cell cycle regulation.
Liao H; Ji F; Ying S
Aging (Albany NY); 2017 Dec; 9(12):2465-2466. PubMed ID: 29242409
[No Abstract] [Full Text] [Related]
13. PRAMEing a picture of differentiation therapy for AML?
Redner RL
Clin Cancer Res; 2013 May; 19(9):2277-9. PubMed ID: 23532884
[TBL] [Abstract][Full Text] [Related]
14. c-Myc plays part in drug resistance mediated by bone marrow stromal cells in acute myeloid leukemia.
Xia B; Tian C; Guo S; Zhang L; Zhao D; Qu F; Zhao W; Wang Y; Wu X; Da W; Wei S; Zhang Y
Leuk Res; 2015 Jan; 39(1):92-9. PubMed ID: 25443862
[TBL] [Abstract][Full Text] [Related]
15. Artemis links ATM to G2/M checkpoint recovery via regulation of Cdk1-cyclin B.
Geng L; Zhang X; Zheng S; Legerski RJ
Mol Cell Biol; 2007 Apr; 27(7):2625-35. PubMed ID: 17242184
[TBL] [Abstract][Full Text] [Related]
16. PRAME-induced inhibition of retinoic acid receptor signaling-mediated differentiation--a possible target for ATRA response in AML without t(15;17).
Bullinger L; Schlenk RF; Götz M; Botzenhardt U; Hofmann S; Russ AC; Babiak A; Zhang L; Schneider V; Döhner K; Schmitt M; Döhner H; Greiner J
Clin Cancer Res; 2013 May; 19(9):2562-71. PubMed ID: 23444226
[TBL] [Abstract][Full Text] [Related]
17. Two distinct controls of mitotic cdk1/cyclin B1 activity requisite for cell growth prior to cell division.
Miyazaki T; Arai S
Cell Cycle; 2007 Jun; 6(12):1419-25. PubMed ID: 17592253
[TBL] [Abstract][Full Text] [Related]
18. When CDK1 rides the telomere cycle.
Teixeira MT; Gilson E
Mol Cell; 2006 Nov; 24(4):491-2. PubMed ID: 17188029
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of mammalian target of rapamycin signaling potentiates the effects of all-trans retinoic acid to induce growth arrest and differentiation of human acute myelogenous leukemia cells.
Nishioka C; Ikezoe T; Yang J; Gery S; Koeffler HP; Yokoyama A
Int J Cancer; 2009 Oct; 125(7):1710-20. PubMed ID: 19507250
[TBL] [Abstract][Full Text] [Related]
20. AML bearing the translocation t(11;17)(q23;q21): involvement of MLL and a region close to RARA, with no differentiation response to retinoic acid.
Classen CF; Teigler-Schlegel A; Röttgers S; Reinhardt D; Döhner K; Debatin KM
Ann Hematol; 2005 Nov; 84(12):774-80. PubMed ID: 16044313
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
